

Reimbursement and clinic reference guide


Barostim Patient Flow

Patient identification · ICD consult HF hospitalization · HF diagnostic alert · EMR screening Patient assessment · Symptomatic despite GDMT Recent echo (LVEF ≤ 35%) • EKG (not CRT candidate) • Baseline NT-proBNP (< 1600 pg/mL) May require medical optimization and re-test · Consider carotid doppler Prior authorization CVRx Patient Access Support (C-PAS) · Submit required documentation (NYHA class, EKG, Echocardiogram, NT-proBNP) Pre-implant consultation · Confirm carotid doppler (< 50% stenosis & anatomy) **Implant** CVRx rep attendance · Consider device rep attendance for other implanted devices Wound check · Implant + 1 week Titration phase · CVRx rep attendance Typically three titration visits (1/month) Depending on the patient, the titration phase can extend through 3-6 months Routine follow-up · Every 6 months

Cardiologist HF Specialist Electrophysiologist

Vascular Surgeon CT Surgeon Electrophysiologist

Patient assessment



^{*} NYHA Class II with a recent history of NYHA Class III LBBB - Left Bundle Branch Block CRT - Cardiac Resynchronization Therapy ICD - Implantable Cardioverter Defibrillator

Barostim indications4

- NYHA III or NYHA II (with recent NYHA III) on GDMT*
- UVEF ≤ 35%
- Not Indicated for CRT**
- NT-proBNP < 1600 pg/mL</p>

Contraindications

- Been assessed to have bilateral carotid bifurcations located above the level of the mandible
- · Baroreflex failure or autonomic neuropathy
- Uncontrolled, symptomatic cardiac bradyarrhythmias
- Carotid atherosclerosis that is determined by ultrasound or angiographic evaluation greater than 50%. Ulcerative plaques in the carotid artery as determined by ultrasound or angiographic evaluation
- · Known allergy to silicone or titanium
- NOTE: Boston Scientific's S-ICD device is contraindicated for patients with unipolar pacing devices.
- · Barostim uses unipolar stimulation.

^{*}Guideline directed medical therapy (GDMT) according to AHA/ACC/ESC guidelines

^{**}Or not receiving adequate response from existing CRT device

^{1.} Yancy CM, et al. Circulation. 2013;128: 2013;128:e240-e327;

^{2.} https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P180050. Accessed March 30, 2021; 3 CVRx data on file.

^{4.} Tracy CM, et al. Circulation. 2012;126:1784-1800

Prior authorization

Barostim requires prior authorization approvals based on the patient medical necessity criteria.

CVRx offers a Patient Access Support (C-PAS) to help.

C-PAS provides case-by-case support for providers who perform Barostim implantation procedures. It is a HIPAA compliant entity and offers assistance for the following services:

- 1. Coding and coverage information
- 2. Eligibility and benefit verification
- 3. Prior authorization
- 4. Pre-determination or certification
- 5. Pre and post service appeals

To enroll in the C-PAS service or submit a request online:

www.cvrx.com/healthcare-professionals/reimbursement

Contact the CVRx helpline for copies of the forms or with any questions:

Email: **c-pas@cvrx.com** Phone: 763-416-2344 Fax: 855-710-7053

Titration

| Implant | 2-3 Weeks | 1-2 Months | 3 Months | 6 Months |
|--------------------|-----------------------------|---------------|-------------------------|----------------------|
| OFF or low dose | Minimal therapy increase | | Therapy optimization | Routine follow-up |

Recommended titration schedule

- Off or low dose of 1mA at implant
- Minimal therapy increase approximately 2-3 weeks after implant. Titrate no higher than 2mA if the first follow up visit is sooner than week 3.
- Week 3 to month 3 should be a gradual increase in therapy while avoiding undesirable extraneous stim or problematic BP/HR
- The goal is to reach maximum tolerated therapy between 3 and 6 months.

For initial titration visits

- 1.) Set frequency to 40 pps
- 2.) Set pulse width to 125 µs
- (3.) Start with a pulse amplitude of 1.0 mA
- 4.) Increase pulse amplitude in 0.2 or 0.4 mA increments until:
 - Symptoms are reported, ex. extraneous stim OR
 - Problematic BP/HR. (Check BP at full point intervals (2.0mA, 3.0, 4.0 etc))
- (5.) Reduce pulse amplitude in 0.4 mA steps until symptoms resolve
- (6.) Always set therapy 0.4 to 1 mA below any extraneous level (i.e. Ext stim at 6mA set therapy between 5 mA and 5.6 mA)

Follow-up

Routine follow-up phase

Once a patient has completed their titration phase, they enter into the routine follow-up phase.

Generally, patients with a chronic Barostim device should be medically treated as if the Barostim was not in place.

Timing

- Every six months patients should return to their doctor's office for a check of the battery status and lead impedance.
- The Barostim therapy generator is designed to have an average battery life of 5 years with no charging required.

Unscheduled or urgent device checks

- Unlike pacemakers or ICDs, Barostim is not providing beat-to-beat life supporting therapy and a malfunction should not be life threatening.
- However, on rare occasions if the patient is experiencing stimulation in the neck, the therapy can be suspended
 with a magnet. Therapy will remain off as long as the magnet is in place. Therapy adjustments can then be made
 when programming is convenient.

CVRx field representatives are available to support device follow-ups and to train staff to perform routine device status checks.

Reimbursement

Reimbursement information provided by CVRx is gathered from 3rd party sources and is presented for illustrative purposes only. This information does not constitute legal or reimbursement advice. CVRx makes no representation or warranty regarding this information or its completeness, accuracy, timeliness or applicability with any particular patient. CVRx specifically disclaims liability or responsibility for the results or consequences of any actions taken in reliance on information in this document. CVRx encourages providers to submit accurate and appropriate claims for services. Laws, regulations and payer policies concerning reimbursement are complex and change frequently. Providers are responsible for making appropriate decisions related to coding and reimbursement submissions. Accordingly, CVRx recommends that customers consult with their payers, reimbursement specialists and/or legal counsel regarding coding, coverage and reimbursement matters.

Checklist for physician billing submissions

- Barostim FDA approval letter
- Barostim pivotal trial publication
- In the claim form Item 19, or on the electronic form 837P-Loop, REF02, REF01=P4, enter a crosswalk CPT code I and verbiage around the expected reimbursement for that code in the dollar amount. (See example on Page 9)
- Paper claim CMS 1500 or electronic equivalent. Please ensure the Prior Authorization number is included in every claim submitted to commercial insurance providers.
- O Detailed medical notes (operative report) which capture both the procedural information that documents the time and complexity of the work associated with the service and the patient's medical condition

Checklist for facility billing submissions

- Barostim FDA approval letter
- Barostim pivotal trial publication
- Please ensure the Prior Authorization number is included in every claim submitted to commercial insurance providers.
- O Please ensure Barostim specific procedure codes are used for both outpatient (CPT 0266T and C1825) or inpatient coding (0JH60MZ and 03HK3MZ)
- UB-04 (outpatient or inpatient) or electronic equivalent

Contact CVRx with any questions:

Email: c-pas@cvrx.com Phone: 763-416-2344

System implant - diagnosis codes

| ICD-10-CM | Descriptor | CC | МСС |
|-----------|--|----|-----|
| 150.1 | Left ventricular failure, unspecified | Х | |
| 150.21 | Acute systolic (congestive) heart failure | | Χ |
| 150.22 | Chronic systolic (congestive) heart failure | X | |
| 150.23 | Acute on chronic systolic (congestive) heart failure | Х | |
| 150.3 | Diastolic (congestive) heart failure | Χ | |
| 150.31 | Acute diastolic (congestive) heart failure | | Χ |
| 150.32 | Chronic diastolic (congestive) heart failure | Χ | |
| 150.33 | Acute on chronic diastolic (congestive) heart failure | | Χ |
| 150.4 | Combined systolic (congestive) and diastolic (congestive) heart failure | Х | |
| 150.41 | Acute combined systolic (congestive) and diastolic (congestive) heart failure | | X |
| 150.42 | Chronic combined systolic (congestive) and diastolic (congestive) heart failure | X | |
| 150.43 | Acute on chronic combined systolic (congestive) and diastolic (congestive) heart failure | | X |
| 150.8 | Other heart failure | | |
| 150.81 | Right heart failure | | |
| I50.811 | Acute right heart failure | | |
| 150.812 | Chronic right heart failure | | |
| 150.813 | Acute on chronic right heart failure | | |
| I50.814 | Right heart failure due to left heart failure | | |
| 150.82 | Biventricular heart failure | | |
| 150.83 | High output heart failure | | |
| 150.84 | End stage heart failure | | |
| 150.89 | Other heart failure | | |
| 150.9 | Heart failure, unspecified | | |

System implant - physician billing

Physician system implant code (this code is used for billing)


| CPT® code Descriptor 0266T Implantation or replacement of carotid sinus baroreflex activation device; total sys | |
|--|--|
| | |

Barostim system implant is reported with Category III CPT codes. When submitting information system codes, providers may choose to reference a comparative Category I CPT procedure code with similar or equivalent resources (i.e. RVUs) to the Barostim implant in the claims form box 19.

Example Comparative codes (these codes are examples, they are not billed)

| Comparative code | Descriptor | Work RVU |
|------------------|--|----------|
| 35301 | Thromboendarterectomy, | 21.16 |
| 33249 | Insertion or replacement of permanent implantable defibrillator system | 14.92 |
| 64568 | Incision for implantation of cranial nerve (eg, vagus nerve) neurostimulator electrode array and pulse generator | 9.00 |

System implant physician billing sample



System implant - outpatient hospital billing

| CPT® code | Descriptor | Status indicator | APC |
|-----------|---|------------------|------|
| 0266T | Implantation or replacement of carotid sinus baroreflex activation device; total system | J1 | 5465 |


J1 - Hospital Part B services paid through a Comprehensive APC (C-APC). Comprehensive APCs (C-APCs) were established for certain payment groups (e.g., device intensive) whereby Medicare only reimburses a single C-APC on a date of service.

| HCPCS code | Descriptor | APC |
|------------|--|------|
| C1825 | Generator, neurostimulator (implantable), non-rechargeable with carotid sinus baroreceptor stimulation lead(s) | 2030 |

Medicare outpatient and ambulatory surgery center implant cases involving the use of Barostim system are eligible for Transitional Pass-Through Payment.

Contact the CVRx Reimbursement team for initial chargemaster set up at 763-416-2344 or reimbursement@cvrx.com.

Outpatient UB-04 sample




System implant - inpatient hospital billing

| ICD-10-PCS procedure code | Descriptor | | cal MS-DRG gnment |
|---------------------------|--|-----|----------------------|
| 0JH60MZ | Insertion of stimulator generator into chest subcutaneous tissue and fascia, open approach | 252 | with MCC |
| AND | cabeataneeds tiesde and raceta, open approach | | |
| 03НК3МZ | Insertion of stimulator lead into right internal carotid artery, percutaneous approach | 253 | with CC |
| <u>OR</u> | artery, percatamocae approach | | |
| 03HL3MZ | Insertion of stimulator lead into left internal carotid artery, percutaneous approach | 254 | without CC/MCC |

Medicare hospital inpatient system implant cases involving the use of Barostim system are eligible for New Technology Add-On Payment.

Contact CVRx Reimbursement team for initial chargemaster set up at 763-416-2344 or reimbursement@cvrx.com.

Inpatient UB-04 sample



Follow-up - physician billing

Possible **primary diagnosis** codes for interrogation and programming. Possible **secondary diagnosis** codes for interrogation and programming are Heart Failure diagnosis codes (see page 3)

| Code | Descriptor | |
|--------|--|--|
| Z45.09 | Encounter for adjustment and management of other cardiac device | |
| Z45.89 | Encounter for adjustment and management of other implanted devices | |

Follow up visits or services may be billed independently from the Barostim device interrogation (with or without programming) and evaluation visits.

Part 1 Physician billing: follow up visit CPT codes

Category III CPT codes are not assigned global periods, so any subsequent visits or services may be billed independently from the initial procedure. The following E/M CPT codes may be used to report follow-up visits. If device interrogation/programming is also performed, the -25 modifier may be added to the E/M code to indicate that it is a separate service.

| CPT® code³ | Descriptor | |
|------------|---|--|
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, Typically, 5 minutes are spent performing or supervising these services. | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, which requires at least 2 of these 3 key components: A problem focused history; A problem focused examination; Straightforward medical decision making. Typically, 10 minutes are spent face-to-face with the patient and/or family. | |
| 99213 | Office or other outpatient visit for the evaluation and management of an established patient, which requires at least 2 of these 3 key components: An expanded problem focused history; An expanded problem focused examination; Medical decision making of low complexity. Typically, 15 minutes are spent face-to-face with the patient and/or family | |
| 99214 | Office or other outpatient visit for the evaluation and management of an established patient, which requires at least 2 of these 3 key components: A detailed history; A detailed examination; Medical decision making of moderate complexity. Typically, 25 minutes are spent face-to-face with the patient and/or family. | |
| 99215 | Office or other outpatient visit for the evaluation and management of an established patient, which requires at least 2 of these 3 key components: A comprehensive history; A comprehensive examination; Medical decision making of high complexity. Typically, 40 minutes are spent face-to-face with the patient and/or family. | |

Follow-up - physician coding and billing (continued)

Part 2 Physician billing: follow-up visit device interrogation with programming

Whenever programming is performed, it is essential that physicians individually document the specific parameters changed for coding purposes. Barostim device interrogation is reported with Category III CPT codes. When submitting claim information, providers may choose to reference a comparative Category I CPT procedure code with similar or equivalent resources (i.e. RVUs) to the Barostim implant in the claims form box 19.

This code is used for billing:

CPT 0273T - Interrogation device evaluation with programming

Interrogation device evaluation (in person), carotid sinus baroreflex activation system, including telemetric iterative communication with the implantable device to monitor device diagnostics and programmed therapy values, with interpretation and report; with programming

Example Comparative codes (these codes are examples, they are not billed):

| Comparative codes | Descriptor | Code | RVU |
|--|--|-------|------|
| Programming device evaluation (in person) with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with analysis, review and report | multiple lead transvenous implantable defibrillator system | 93284 | 3.21 |
| | multiple lead pacemaker system | 93281 | 2.57 |
| | single lead transvenous implantable defibrillator system | 93282 | 2.45 |
| by a physician or other qualified health care professional | | | |

This code is used for billing:


CPT 0272T - Interrogation device evaluation

Interrogation device evaluation (in person), carotid sinus baroreflex activation system, including telemetric iterative communication with the implantable device to monitor device diagnostics and programmed therapy values, with interpretation and report (eg, battery status, lead impedance, pulse amplitude, pulse width, therapy frequency, pathway mode, burst mode, therapy start/stop times each day)

Example Comparative codes (these codes are examples, they are not billed):

| Comparative codes | Descriptor | Code | RVU |
|--|---|-------|------|
| Interrogation device evaluation (in person) with analysis, review and | single, dual, or multiple lead transvenous implantable defibrillator system, including analysis of heart rhythm derived data elements | 93289 | 2.21 |
| report by a physician or other qualified health care | implantable subcutaneous lead defibrillator system | 93261 | 2.13 |
| professional, includes connection, recording and disconnection per patient encounter | single, dual, or multiple lead pacemaker system, or leadless pacemaker system | 93288 | 1.73 |

Follow up and device titration physician billing sample



Additional reimbursement information

1500 Form locator

| Item number | Title | Notes |
|------------------|---|---|
| Item 19 | Additional Claim Information | Enter crosswalk CPT code I and verbiage around the expected reimbursement for that code in dollar amount |
| Item 21 (1-4) | Diagnosis or Nature of Illness or Injury | Enter the ICD-10 CM diagnosis codes to identify the patient's diagnosis and/or condition |
| Item 23 | Prior Authorization Number | Enter payer's prior authorization number (if obtained prior to the procedure) |
| Item 24D | Procedures, Services or Supplies | Enter CPT codes for each procedure or service rendered, with one CPT code in each line. Include modifiers if needed, eg80, if assistant surgeon |
| Item 24E | Diagnosis Pointer | Point the services in 24 D to the diagnosis codes listed in 21 1-4 |

Generator replacement - physician billing

Physician generator replacement code (this code is used for billing)

CPT® code³

Descriptor

Battery replacement


Implantation or replacement of carotid sinus baroreflex activation device; pulse generator only (includes intra-operative interrogation, programming, and repositioning, when performed)

Barostim generator replacement is reported with Category III CPT codes. When submitting claim information, providers may choose to reference a comparative Category I CPT procedure code with similar or equivalent resources (i.e. RVUs) to the Barostim implant in the claims form box 19.

Example Comparative codes (these codes are examples, they are not billed)

| Comparativ | re code | Work RVU | | | |
|------------|--|----------|--|--|--|
| 61885 | Insertion or replacement of cranial neurostimulator pulse generator or receiver, direct or inductive coupling; with connection to a single electrode array | 6.05 | | | |

Generator replacement physician billing sample



Generator replacement - outpatient hospital billing

| CPT® code³ | Descriptor | Status indicator | APC |
|-----------------|--|---------------------|------|
| Battery replace | cement | | |
| 0268T | Implantation or replacement of carotid sinus baroreflex activation device; pulse generator only (includes intra-operative interrogation, programming, and repositioning, when performed) | J1 | 5465 |

HCPCS level II device codes

The following HCPCS Level II codes should be used for cost reporting purposes when reporting Barostim generator replacement. In general, C-codes are used for billing Medicare and L-codes are used for billing private payers, although some private payers may also accept C-codes.

| HCPCS5 code | e Descriptor |
|----------------|---|
| Battery and le | ad replacement |
| C1767 | Generator, neurostimulator (implantable), non-rechargeable |
| C1778 | Lead, neurostimulator (implantable) |
| L8686 | Implantable neurostimulator pulse generator, single array, non-rechargeable, includes extension |
| L8680 | Implantable neurostimulator electrode, each |

Generator replacement outpatient UB-04 sample

| 31 CODE | OCCUR | RENCE 32 OCCURRENCE DATE CODE DATE | 33 OCCURRED CODE D | NCE ATE | 34 OCCURRENCE CODE DATE | 35 CODE | OCCURRENCE SPA FROM | | 36 CODE | OCCURRENCE SPA FROM | N THROUGH | 37 | |
|------------|---------|------------------------------------|--------------------|------------|-----------------------------|------------------|-------------------------|----------------|------------|------------------------|--------------|-----------------------|----|
| | | | | | | | | | | | | | |
| 38 | | | | | | 39 CO | VALUE CODE DE AMOUNT | S 40 CO | DE | VALUE CODES AMOUNT | 41 CODE | VALUE CODES AMOUNT | |
| | TIENT N | NAME ADDRESS | | | | a b c d | | | | | | | |
| 42 REV | (. CD. | 43 DESCRIPTION | | | 44 HCPCS / RATE / HIPPS COD | E | 45 SERV. DATE | 46 SERV. UNITS | | 47 TOTAL CHARGES | 48 NON-C | OVERED CHARGES | 49 |
| 013 | 0 | EKG | | | | | | # | | \$XXXXX XX | | : | |
| 025 | 0 | PHARMACY | | | | | | # | | \$XXXXX XX | | - | |
| 025 | 8 | IV SOLUTION | | | | | | # | | \$XXXXX XX | | 1 | |
| 027 | 0 | MEDICAL / SURGICAL SUPPLIES | | | | | | # | | \$XXXXX XX | | | |
| 027 | 8 | OTHER DEVICE / IMPLANT | | | C1767 | | 01012022 | 1 | | \$XXXXX XX | | i | |
| 036 | 0 | OPERATING ROOM | | | 0268T | | 01012022 | 1 | | \$XXXXX XX | | | |
| 037 | 0 | ANESTHESIA | | | | | | # | | \$XXXXX XX | | į | |
| 071 | 0 | RECOVERY ROOM | | | | | | # | | \$XXXXX XX | | : | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | : | |

Ambulatory surgery center

Procedures involving the Barostim System may be also performed in the Ambulatory Surgery Centers (ASC). The following CPT codes may be used as a guide for Ambulatory Surgery Center (ASC) reporting.

Medicare outpatient ambulatory surgery center implant cases involving the use of Barostim system are eligible for Transitional Pass-Through Payment.

| CPT® code³ | Descriptor | ASC payment indicator | | |
|---------------|---|-----------------------------|--|--|
| Insertion/Rep | lacement | | | |
| 0266T | Implantation or replacement of carotid sinus baroreflex activation device; total system (includes generator placement, unilateral or bilateral lead placement, intra-operative interrogation, programming, and repositioning, when performed) | J8 | | |
| 0268T | Implantation or replacement of carotid sinus baroreflex activation device; pulse generator only (includes intra-operative interrogation, programming, and repositioning, when performed) | J8 | | |
| Revision/Rem | noval | | | |
| 0269T | Revision or removal of carotid sinus baroreflex activation device; total system (includes generator placement, unilateral or bilateral lead placement, intra-operative interrogation, programming, and repositioning, when performed) | G2 | | |
| 0270T | Revision or removal of carotid sinus baroreflex activation device; lead only, unilateral (includes intra-operative interrogation, programming, and repositioning, when performed) | G2 | | |
| 0271T | Revision or removal of carotid sinus baroreflex activation device; pulse generator only (includes intra-operative interrogation, programming, and repositioning, when performed) | G2 | | |

J8 – Device intensive procedure, paid at adjusted rate

G2 - Non office-based surgical procedure added in CY 2008 or later; payment based on OPPS relative payment weight

Reimbursement appendix

| CPT® code³ | Descriptor | Status indicator | APC |
|------------|--|---------------------|------|
| 0266T | Implantation or replacement of carotid sinus baroreflex activation device; total system | J1 | 5465 |
| 0267T | Implantation or replacement of carotid sinus baroreflex activation device; lead only, unilateral (includes intra-operative interrogation, programming, and repositioning, when performed) | J1 | 5461 |
| 0268T | Implantation or replacement of carotid sinus baroreflex activation device; pulse generator only (includes intra-operative interrogation, programming, and repositioning, when performed) | J1 | 5465 |
| 0269T | Revision or removal of carotid sinus baroreflex activation device; total system (includes generator placement, unilateral or bilateral lead placement, intra-operative interrogation, programming, and repositioning, when performed) | Q2 | 5432 |
| 0270T | Revision or removal of carotid sinus baroreflex activation device; lead only, unilateral (includes intra-operative interrogation, programming, and repositioning, when performed) | J1 | 5461 |
| 0271T | Revision or removal of carotid sinus baroreflex activation device; pulse generator only (includes intra-operative interrogation, programming, and repositioning, when performed) | J1 | 5461 |
| 0272T | Interrogation device evaluation (in person), carotid sinus baroreflex activation system, including telemetric iterative communication with the implantable device to monitor device diagnostics and programmed therapy values, with interpretation and report (eg, battery status, lead impedance, pulse amplitude, pulse width, therapy frequency, pathway mode, burst mode, therapy start/stop times each day) | S | 5721 |
| 0273T | Interrogation device evaluation (in person), carotid sinus baroreflex activation system, including telemetric iterative communication with the implantable device to monitor device diagnostics and programmed therapy values, with interpretation and report; with programming | S | 5721 |

Hospital Outpatient Status Indicator:

J1- Hospital Part B services paid through a Comprehensive APC (C-APC). Comprehensive APCs (C-APCs) were established for certain payment groups (e.g., device intensive) whereby Medicare only reimburses a single C-APC on a date of service.

Q2- Packaged APC payment if billed on the same claim as a HCPCS code assigned status indicator "T".

S- Procedure or Service, Not Discounted When Multiple; *Medicare rate for 2021

CVRx contacts

Contact

Technical support (24/7) Phone: +1 763-416-2343

Reimbursement

Phone: 763-416-2344 Fax: 855-710-7053

Email: reimbursement@cvrx.com

Prior authorization

Email: c-pas@cvrx.com www.cvrx.com/reimbursement

| Local Team | |
|------------------|--|
| Sales | |
| Clinical support | |
| Training | |

References:

Physician Billing

- 1 https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P180050
- 2 ICD-10-CM 2022. American Medical Association, Chicago, IL 2019.
- 3 Current Procedural Terminology 2022, American Medical Association. Chicago, IL 2022. CPT is a registered trademark of the American Medical Association. Current Procedural Terminology (CPT®) is copyright 2018 American Medical Association. All Rights Reserved. Applicable FARS/ DFARS apply.
- 4 https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P180050 National Uniform Claim Committee, 1500 Health Insurance Claim Form Reference Instruction Manual. Version 9.1 5/14. 1 https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P180050

- 1 Current Procedural Terminology 2022, American Medical Association. Chicago, IL 2022. CPT is a registered trademark of the American Medical Association. Current Procedural Terminology (CPT®) is copyright 2018 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply. 2 ICD-10-PCS and ICD-10-CM 2022. American Medical Association, Chicago, IL 2019.
- 3 2020 IPPS Final Rule. CMS-1716-F.
- 4 2022 OPPS and ASC Final Rule. CMS-1753-FC.
- 5 2022 HCPCS Level II Expert. AAPC, Salt Lake City, UT 2019.
- 6 https://www.cms.gov/newsroom/fact-sheets/cy-2021-medicare-hospital-outpatient-prospective-payment-system-and-ambulatory-surgical-center-0

Barostim™ Brief Summary for Physicians

The Barostim System is indicated for the improvement of symptoms of heart failure—quality of life, six-minute hall walk and functional status—for patients who remain symptomatic despite treatment with guideline-directed medical therapy, are NYHA Class III or Class II (who had a recent history of Class III), have a left ventricular ejection fraction ≤ 35%, a NT-proBNP < 1600 pg/ml and excluding patients indicated for Cardiac Resynchronization Therapy (CRT) according to AHA/ACC/ESC guidelines.

Patients are contraindicated if they have been assessed to have bilateral carotid bifurcations located above the level of the mandible, baroreflex failure or autonomic neuropathy, uncontrolled symptomatic cardiac bradyarrhythmias, carotid atherosclerosis that is determined by ultrasound or angiographic evaluation greater than 50%, ulcerative plaques in the carotid artery as determined by ultrasound or angiographic evaluation, known allergy to silicone or titanium.

Warnings include: only trained physicians may use this system, prescribing physicians should be experienced in the diagnosis and treatment of heart failure and should be

Warnings include: only trained physicians may use this system, prescribing physicians should be experienced in the diagnosis and treatment of heart failure and should be familiar with the use of this system, monitor blood pressure and heart rate during Carotid Sinus Lead placement and when adjusting stimulation parameters intra-operatively, post-implantation, program the system to avoid the following: heart rate falls below 50 beats per minute (BPM), or systolic pressure falls below 90 mmHg, or diastolic blood pressure falls below 50 mmHg, or problematic adjacent tissue stimulation is noted, or undesirable interaction indicated by monitoring of any other implanted electrical device (see "Device Interaction Testing" in Section 10), or any other potentially hazardous patient responses are observed. Do not use Magnetic Resonance Imaging (MRI) on patients implanted with the system. Improper system implantation could result in serious injury or death. Do not use diathermy therapy including shortwave, microwave, or therapeutic ultrasound diathermy on patients implanted with the system. Patients should be counseled to stay at least 15 cm (6 inches) away from devices with strong electrical or magnetic fields such as strong magnets, loudspeaker magnets, Electronic Article Surveillance (EAS) system tag deactivators, are welders, induction furnaces, and other similar electrical or electromechanical devices. This would include not placing items such as earphones in close proximity to the implanted pulse generator. The IPG may affect the operation of other implanted devices such as cardiac defibrillators, pacemakers, or neurological stimulation systems. For patients who currently have an implanted electrical medical device, physicians must verify compatibility with the implanted device during implantation of the system. Contralateral implant of the Barostim NEO IPG may help to reduce potential interactions. Interactions are more likely in devices that contain a sensing function, such as an implantable cardiac defibrillator

Precautions include: the system should be implanted and programmed carefully to avoid stimulation of tissues near the electrode or in the area of the IPG pocket. Such extraneous stimulation could involve the following: the regional nerves, causing laryngeal irritation, difficulty swallowing, or dyspnea, the cervical musculature, causing intermittent contraction, skeletal muscles, causing intermittent contraction around the IPG pocket. Proper sterile technique during implantation should be practiced and aggressive pre-operative antibiotics are recommended. Infections related to any implanted device are difficult to treat and may necessitate device explanation.

It is anticipated that subjects will be exposed to operative and post-operative risks similar to related surgical procedures involving the neck and/or a pacemaker implant. These risks and potential risks of chronic device based baroreflex activation may include, but are not limited to: stroke, transient ischemic attack (TIA), systemic embolization, surgical or anesthetic complications, infection, wound complications, arterial damage, pain, nerve damage/stimulation, hypotension, hypotension, hypotension, respiratory, exacerbation of heart failure, cardiac arrhythmias, tissue erosion/IPG migration, injury to baroreceptors, fibrosis, allergic reaction, general injury to user or patient, need for reoperative procedure, and death.

Disclaimer: Reimbursement information provided by CVRx is gathered from 3rd party sources and is presented for illustrative purposes only. This information does not constitute legal or reimbursement advice. CVRx makes no representation or warranty regarding this information or its completeness, accuracy, timeliness or applicability with any particular patient. CVRx specifically disclaims liability or responsibility for the results or consequences of any actions taken in reliance on information in this document. CVRx encourages providers to submit accurate and appropriate claims for services. Laws, regulations and payer policies concerning reimbursement are complex and change frequently. Providers are responsible for making appropriate decisions related to coding and reimbursement submissions. Accordingly, CVRx recommends that customers consult with their payers, reimbursement specialists and/or legal counsel regarding coding, coverage and reimbursement matters.

CVRx. Inc. 9201 West Broadway Ave., Suite 650 Minneapolis, MN 55445 Phone: (763) 416-2840 Fax: (763) 416-2841 www.cvrx.com CAUTION: Federal law restricts this device to sale by or on the order of a physician.

